MYH11 is altered in 0.21% of acute myeloid leukemia patients [3].

MYH11 is an inclusion criterion in 60 clinical trials for acute myeloid leukemia, of which 24 are open and 36 are closed. Of the trials that contain MYH11 status and acute myeloid leukemia as inclusion criteria, 22 are phase 1 (5 open), 7 are phase 1/phase 2 (4 open), 16 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (4 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [4].

MYH11 is an inclusion criterion in 18 clinical trials for myelodysplastic syndromes, of which 9 are open and 9 are closed. Of the trials that contain MYH11 status and myelodysplastic syndromes as inclusion criteria, 10 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 13 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 6 are closed. Of the trials that contain MYH11 status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 8 clinical trials for chronic myeloid leukemia, of which 4 are open and 4 are closed. Of the trials that contain MYH11 status and chronic myeloid leukemia as inclusion criteria, 5 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [4].

MYH11 is an inclusion criterion in 6 clinical trials for hodgkin lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MYH11 status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open) and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 6 clinical trials for multiple myeloma, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open) and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [4].

MYH11 is an inclusion criterion in 5 clinical trials for acute biphenotypic leukemia, of which 1 is open and 4 are closed. Of the trials that contain MYH11 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 4 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain MYH11 status and chronic myelomonocytic leukemia as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].

MYH11 is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 2 are open and 2 are closed. Of the trials that contain MYH11 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 4 clinical trials for refractory anemia with excess blasts, of which 2 are open and 2 are closed. Of the trials that contain MYH11 status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [4].

MYH11 is an inclusion criterion in 3 clinical trials for acute promyelocytic leukemia, of which 0 are open and 3 are closed. Of the trials that contain MYH11 status and acute promyelocytic leukemia as inclusion criteria, 2 are phase 1 (0 open) and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain MYH11 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

MYH11 is an inclusion criterion in 3 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 1 is closed. Of the trials that contain MYH11 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

MYH11 is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain MYH11 status and small lymphocytic lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

MYH11 is altered in 0.2% of acute leukemia patients [3].

MYH11 is an inclusion criterion in 2 clinical trials for acute leukemia, of which 0 are open and 2 are closed. Of the trials that contain MYH11 status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYH11 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [4].

MYH11 is altered in 14.29% of acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 patients [3].

MYH11 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 as inclusion criteria, 1 is phase 4 (1 open) [4].

MYH11 is altered in 7.69% of core binding factor acute myeloid leukemia patients [3].

MYH11 is an inclusion criterion in 1 clinical trial for core binding factor acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and core binding factor acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 as inclusion criteria, 1 is phase 4 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and anaplastic large cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and Burkitt lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and follicular lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mantle cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and prolymphocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for refractory anemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and refractory anemia as inclusion criteria, 1 is phase 2 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MYH11 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].